KRAS and colorectal cancer: The data presented here are consistent with previous reports demonstrating that KRAS and BRAF mutations are mutually exclusive; the prevalence of BRAF mutations (7.2%) is, practically, similar with that reported in other patients' series from a first-line setting [39], but higher than that described in heavily pre-treated colorectal cancer patients [21], [37], indicating that its prognostic significance mainly depends on the studied patients' population.